{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-300538","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2025-11-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.441523+00:00","generated_at":"2026-05-16T16:32:41.728795+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TScan Therapeutics retention program grants cash and RSUs to CEO, CFO, CMO tied to TSC-101 milestone","bullets":["Board approved retention program for CEO Gavin MacBeath, CFO Jason Amello, and CMO Chrystal Louis.","Cash awards: $399K (CEO), $170K (CFO), $250K (CMO); 50% paid upon TSC-101 pivotal trial milestone, 50% on first anniversary.","Equity awards: 1M RSUs (CEO), 270K RSUs (CFO), 650K RSUs (CMO) granted upon milestone; vest 25% at year 2, 75% at trial completion or year 4.","Awards subject to continued employment and terms of 2021 Equity Incentive Plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-300538","json":"https://secwatch.observer/filing/0001193125-25-300538.json","markdown":"https://secwatch.observer/filing/0001193125-25-300538.md","text":"https://secwatch.observer/filing/0001193125-25-300538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000119312525300538/0001193125-25-300538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000119312525300538/d41366d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T16:32:41.728795+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}